Atomoxetine to help prevent fainting from vasovagal episodes
Part of Brain & nervous system clinical trials.
This Phase 3 study tests whether atomoxetine can reduce how often vasovagal fainting happens. It may help people who have frequent fainting episodes with triggers like stress or standing for long periods.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and can give informed consent
- You have had at least 2 vasovagal fainting (syncope) episodes in the last 12 months
- Your fainting episodes come from vasovagal syncope and not another cause
- Your symptom score for people with normal heart structure is high enough to qualify
- You are not pregnant, and you can use reliable birth control during the study
- You have no major heart rhythm or heart valve/conduction problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a procedure called cardioneuroablation for people whose fainting or very slow heartbeat doesn't improve with other treatments. If you are under 60, have no other major heart conditions, and have not had ablation before, it might be an option to reduce or stop your fainting spells.
This Phase 2 study tests whether ondansetron can help prevent future fainting (vasovagal syncope) in adults who have had recent episodes. If it works, it may reduce how often you faint and improve safety in everyday situations.
This trial tests whether the drug ondansetron can prevent fainting that happens during sleep or when waking up. It may help reduce how often you faint and improve your safety at night.
This study looks at people who have had repeated fainting spells and still don’t know the cause. It tests whether different types of heart monitoring (like tilt testing or an ECG/heart tracing) can better explain what’s triggering syncope and guide prevention.
This trial tests a procedure called cardioneuroablation to treat severe fainting (reflex syncope) that hasn't been helped by other treatments. The goal is to see if it reduces fainting without causing dangerous heart rhythm problems.
This study tests a new way to detect and warn about fainting in people with certain types of syncope (temporary loss of consciousness). It may help those who have already had a specific fainting evaluation called an ARS assessment.
Hear when a new Vasovagal Syncope trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.